@article{oai:repo.qst.go.jp:00046605,
 author = {Shinoto, Makoto and Yamada, Shigeru and Yasuda, Shigeo and Imada, Hiroshi and Shioyama, Yoshiyuki and Hiroshi, Honda and Kamada, Tadashi and Tsujii, Hirohiko and Saisho, Hiromitsu and et.al and 篠藤 誠 and 山田 滋 and 安田 茂雄 and 今田 浩史 and 塩山 善之 and 本田  浩 and 鎌田 正 and 辻井 博彦 and 税所 宏光},
 issue = {1},
 journal = {Cancer},
 month = {Jun},
 note = {BACKGROUND: The authors evaluated the tolerance and efficacy of carbon-ion radiotherapy (CIRT) as a short-course, preoperative treatment and determined the recommended dose needed to reduce the risk of postoperative local recurrence without excess injury to normal tissue.
METHODS: Patients radiographically defined with potentially resectable pancreatic cancer were eligible. A preoperative, short-course, dose-escalation study was performed with fixed 8 fractions in 2 weeks. The dose of irradiation was increased by 5% increments from 30 grays equivalents (GyE) to 36.8 GyE. Surgery was to be performed 2 to 4 weeks after the completion of CIRT.
RESULTS: The study enrolled 26 patients. At the time of restaging after CIRT, disease progression with distant metastasis or refusal ruled out 5 patients from surgery. Twenty-one of 26 patients (81%) patients underwent surgery. The pattern of initial disease progression was distant metastasis in 17 patients (65%) and regional recurrence in 2 patients (8%). No patients experienced local recurrence. The 5-year survival rates for all 26 patients and for those who underwent surgery were 42% and 52%, respectively.
CONCLUSIONS: Preoperative, short-course CIRT followed by surgery is feasible and tolerable without unacceptable morbidity. Cancer 2013. © 2012 American Cancer Society.},
 pages = {45--51},
 title = {Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer},
 volume = {119},
 year = {2012}
}